Altogether, this study underscores the promise of combining PARP inhibitors with ATR/CHK1 pathway inhibition to reduce OC cell viability and invasiveness, potentially overcoming the limitations of single-agent therapies in the treatment of epithelial ovarian cancer. This evidence concerns the gene ATR and ovarian carcinoma.